DrugAug 2, 2017
SCA Pharmaceuticals BUPIVacaine HCl 0.1% PF (From 0.75%) in 0.9% Sodium Chloride, 250 mL recall — FDA D-1005-2017
Lack of Assurance of Sterility; product has the potential to leak.
Class IIFDA: TerminatedSCA Pharmaceuticals
10,690drug recall records
953FDA Class I records
8firms with 5+ records
Aidapak Services, LLC537 records
Database records
Records — page 237
10,690 detailed records are currently available in this category.
DrugAug 2, 2017
SCA Pharmaceuticals PHENYLephrine HCl 10 mg in 0.9% Sodium Chloride recall — FDA D-1004-2017
Lack of Assurance of Sterility: Product made with recalled 0.9% sodium chloride bags which have the potential to leak.
Class IIFDA: TerminatedSCA Pharmaceuticals
DrugJul 26, 2017
PharMedium Services Succinylcholine Chloride Injection (Preserved) 20 mg per mL, 200 mg per recall — FDA D-0985-2017
Lack of Assurance of Sterility; media fill failure at manufacturer
Class IIFDA: TerminatedPharMedium Services, LLC
DrugJul 26, 2017
Hospira Inc., A Pfizer Company Argatroban Injection, 250 mg/2.5 mL (100 mg/mL), 5 mL recall — FDA D-0980-2017
Failed Impurities/Degradation Specifications; out of specification result for denitroquinoline-related impurity during three month time point
Class IIIFDA: TerminatedHospira Inc., A Pfizer Company
DrugJul 26, 2017
PharMedium Services Potassium PHOSphate in 0.9% Sodium Chloride Injection, 7 mMol in 100 mL recall — FDA D-0991-2017
Lack of Assurance of Sterility; media fill failure at manufacturer
Class IIFDA: TerminatedPharMedium Services, LLC
DrugJul 26, 2017
Teva Pharmaceuticals USA Buprenorphine and Naloxone Sublingual Tablets, 2 mg/0.5 mg 30 recall — FDA D-0983-2017
Failed Impurities/Degradation Specifications: out of specification test results for related compounds largest unknown impurity.
Class IIIFDA: TerminatedTeva Pharmaceuticals USA
DrugJul 26, 2017
PharMedium Services Potassium PHOSphate in 0.9% Sodium Chloride Injection, 9 mMol in 100 mL recall — FDA D-0994-2017
Lack of Assurance of Sterility; media fill failure at manufacturer
Class IIFDA: TerminatedPharMedium Services, LLC
DrugJul 26, 2017
PharMedium Services Potassium PHOSphate in 0.9% Sodium Chloride Injection, 10 mMol in a) 100 recall — FDA D-0986-2017
Lack of Assurance of Sterility; media fill failure at manufacturer
Class IIFDA: TerminatedPharMedium Services, LLC
DrugJul 26, 2017
PharMedium Services Potassium PHOSphate in 5% Dextrose Injection, 7.5 mMol in 100 mL in 150 recall — FDA D-0993-2017
Lack of Assurance of Sterility; media fill failure at manufacturer
Class IIFDA: TerminatedPharMedium Services, LLC
DrugJul 26, 2017
PharMedium Services Potassium PHOSphate in 0.9% Sodium Chloride Injection, 40 mMol in 250 mL recall — FDA D-0990-2017
Lack of Assurance of Sterility; media fill failure at manufacturer
Class IIFDA: TerminatedPharMedium Services, LLC
DrugJul 26, 2017
PharMedium Services Potassium PHOSphate in 5% Dextrose Injection, 9 mMol in 50 mL in 50 mL recall — FDA D-0995-2017
Lack of Assurance of Sterility; media fill failure at manufacturer
Class IIFDA: TerminatedPharMedium Services, LLC
DrugJul 26, 2017
Teva Pharmaceuticals USA Buprenorphine and Naloxone Sublingual Tablets 8 mg/2 mg 30 tablets recall — FDA D-0984-2017
Failed Impurities/Degradation Specifications: out of specification test results for related compounds largest unknown impurity.
Class IIIFDA: TerminatedTeva Pharmaceuticals USA
DrugJul 26, 2017
PharMedium Services Potassium PHOSphate in 5% Dextrose Injection, 15 mMol in 250 mL in 250 recall — FDA D-0997-2017
Lack of Assurance of Sterility; media fill failure at manufacturer
Class IIFDA: TerminatedPharMedium Services, LLC
DrugJul 26, 2017
PharMedium Services Potassium PHOSphate in 0.9% Sodium Chloride Injection 15 mMol in a) 100 recall — FDA D-0987-2017
Lack of Assurance of Sterility; media fill failure at manufacturer
Class IIFDA: TerminatedPharMedium Services, LLC
DrugJul 26, 2017
PharMedium Services Potassium PHOSphate in 0.9% Sodium Chloride Injection, 7.5 mMol in 100 recall — FDA D-0992-2017
Lack of Assurance of Sterility; media fill failure at manufacturer
Class IIFDA: TerminatedPharMedium Services, LLC
DrugJul 26, 2017
PharMedium Services Potassium PHOSphate in 0.9% Sodium Chloride Injection, 30 mMol in a) 250 recall — FDA D-0996-2017
Lack of Assurance of Sterility; media fill failure at manufacturer
Class IIFDA: TerminatedPharMedium Services, LLC
DrugJul 26, 2017
PharMedium Services Potassium PHOSphate in 5% Dextrose Injection, 30 mMol 500 mL in 500 mL recall — FDA D-0989-2017
Lack of Assurance of Sterility; media fill failure at manufacturer
Class IIFDA: TerminatedPharMedium Services, LLC
DrugJul 26, 2017
PharMedium Services Potassium PHOSphate in 0.9% Sodium Chloride Injection 20 mMol in 100 mL recall — FDA D-0988-2017
Lack of Assurance of Sterility; media fill failure at manufacturer
Class IIFDA: TerminatedPharMedium Services, LLC
DrugJul 26, 2017
Valeant Pharmaceuticals Obagi-C Rx System C-Therapy Night Cream, Net wt. 2 oz. (57g) bottle recall — FDA D-0998-2017
Labeling: Incorrect or Missing Package Insert - Obagi-C Rx System C-Therapy Night Cream is being recalled due to incomplete packaging/labeling. The bottle is missing the product insert and…
Class IIIFDA: TerminatedValeant Pharmaceuticals North America LLC
DrugJul 19, 2017
SODIUM CHLORIDE 0.9% Sodium Chloride Injection USP, 250 mL VIAFLEX Container bag recall — FDA D-0957-2017
Lack of Assurance of Sterility: Customer complaints for leaking bags.
Class IIFDA: TerminatedBaxter Healthcare Corporation
DrugJul 19, 2017
Organic Herbal Supply ZDaily Daily Testosterone and Llibido Booster Herbal Dietary recall — FDA D-0967-2017
Marketed without an Approved NDA/ANDA; FDA analysis found the presence of undeclared tadalafil, sildenafil and/or their analogues and Flibanserin
Class IFDA: TerminatedOrganic Herbal Supply
DrugJul 19, 2017
Teva Pharmaceuticals Paliperidone Extended-Release Tablets, 3 mg, 90 count bottles recall — FDA D-0960-2017
Failed Dissolution Specifications: Drug release test result, obtained during routine 9-month stability testing, which was below specification for one tablet. Teva cannot at this time…
Class IFDA: TerminatedTeva Pharmaceuticals
DrugJul 19, 2017
Organic Herbal Supply Xrect Male Enhancement Herbal Dietary Supplement Capsules, 500 mg recall — FDA D-0964-2017
Marketed without an Approved NDA/ANDA; FDA analysis found the presence of undeclared tadalafil, sildenafil and/or their analogues and Flibanserin
Class IFDA: TerminatedOrganic Herbal Supply
DrugJul 19, 2017
Organic Herbal Supply ENHANCEROL Herbal Dietary Supplement Capsules, 500 mg, supplied in 2 recall — FDA D-0969-2017
Marketed without an Approved NDA/ANDA; FDA analysis found the presence of undeclared tadalafil, sildenafil and/or their analogues and Flibanserin
Class IFDA: TerminatedOrganic Herbal Supply
How to use this drug recall index
A drug recall record can include the reason for recall, firm, status, distribution pattern, quantity and FDA classification. This site does not provide medical advice; it organizes public recall information and links users back to official sources.
Recall Lookup USA keeps the last complete source record available when an official data service is temporarily unavailable. When a source provides only a few fields, we show only those known facts rather than padding the page with generic text.
What the database can and cannot tell you
This database is designed for discovery and reference. It can help you locate a relevant recall record, identify the recalling firm or NHTSA campaign, compare dates and classifications, and follow the official source. It is not a substitute for a VIN-specific NHTSA check, a manufacturer notice, medical advice or instructions issued by the recalling company.